Anti-Eosinophil Biologics in Chronic Respiratory Diseases
DOI:
https://doi.org/10.53469/jcmp.2024.06(12).26Keywords:
Asthma, Eosinophils, Biologics, Chronic obstructive pulmonary diseaseAbstract
Eosinophils play a crucial role in the pathogenesis of various chronic respiratory conditions. Recent advances in understanding eosinophilic inflammation have promoted the development of biologics aimed at specifically targeting inflammation driven by eosinophils. One such biologic, benralizumab, has shown considerable efficacy and favorable tolerability in individuals with refractory eosinophilic asthma. While the efficacy of these therapies in COPD is less consistent, promising results have been observed in specific eosinophilic subtypes. For CRSwNP, biologics have shown potential in reducing nasal polyp size, alleviating clinical symptoms, and decreasing the need for surgical intervention. In spite of these therapeutic advancements, challenges remain, including high treatment costs and a lack of long-term safety data. Future research should prioritize biomarker identification to optimize patient selection and further individualize these therapies.
References
HUANG L, APPLETON J A. Eosinophils in Helminth Infection: Defenders and Dupes. Trends Parasitol 2016; 32: 798-807.
ROSENBERG H F, DYER K D, FOSTER P S. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 2013; 13: 9-22.
ABDALA-VALENCIA H, CODEN M E, CHIARELLA S E, et al. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. J Leukoc Biol 2018; 104: 95-108.
CHUNG K F, WENZEL S E, BROZEK J L, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-73.
MCBRIEN C N, MENZIES-GOW A. The Biology of Eosinophils and Their Role in Asthma. Front Med (Lausanne) 2017; 4: 93.
DRAKE M G, LEBOLD K M, ROTH-CARTER Q R, et al. Eosinophil and airway nerve interactions in asthma. J Leukoc Biol 2018; 104:61-7.
YANCEY S W, KEENE O N, ALBERS F C, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol 2017; 140:1509-18.
PRICE D B, RIGAZIO A, CAMPBELL J D, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3:849-58.
BARNES P J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016; 138:16-27.
LEIGH R, PIZZICHINI M M, MORRIS M M, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006; 27:964-71.
SINGH D, KOLSUM U, BRIGHTLING C E, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014; 44:1697-700.
NEGEWO N A, MCDONALD V M, BAINES K J, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis 2016; 11:1495-504.
ZEIGER R S, TRAN T N, BUTLER R K, et al. Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease. J Allergy Clin Immunol Pract 2018; 6:944-54.e5.
YUN J H, LAMB A, CHASE R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018; 141:2037-47.e10.
KOLBECK R, KOZHICH A, KOIKE M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010; 125:1344-53.e2.
LAVIOLETTE M, GOSSAGE D L, GAUVREAU G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132:1086-96.e5.
BUSSE W W, KATIAL R, GOSSAGE D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125:1237-44.e2.
CASTRO M, WENZEL S E, BLEECKER E R, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2:879-90.
BLEECKER E R, FITZGERALD J M, CHANEZ P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115-27.
PARK H S, KIM M K, IMAI N, et al. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan. Int Arch Allergy Immunol 2016; 169: 135-45.
BLEECKER E R, WECHSLER M E, FITZGERALD J M, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J 2018;52.
BUSSE W W, BLEECKER E R, FITZGERALD J M, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 2019; 7:46-59.
BUSSE W W, BLEECKER E R, FITZGERALD J M, et al. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. J Allergy Clin Immunol 2021; 148:266-71.e2.
KORN S, BOURDIN A, CHUPP G, et al. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract 2021; 9:4381-92.e4.
NAIR P, WENZEL S, RABE K F, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med 2017; 376:2448-58.
JACKSON D J, HEANEY L G, HUMBERT M, et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet 2024; 403:271-81.
BRIGHTLING C E, BLEECKER E R, PANETTIERI R A, JR., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014; 2:891-901.
CRINER G J, CELLI B R, BRIGHTLING C E, et al. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med 2019; 381:1023-34.
SINGH D, CRINER G J, AGUSTí A, et al. Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis. Int J Chron Obstruct Pulmon Dis 2023; 18:1595-9.
WAUTLET A, BACHERT C, DESROSIERS M, et al. The Management of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With Biologics. J Allergy Clin Immunol Pract 2023; 11:2642-51.
DE PRINS L, RAAP U, MUELLER T, et al. White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA. Front Allergy 2022; 3:889221.
STEVENS W W, PETERS A T, HIRSCH A G, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2017; 5:1061-70.e3.
EMSON C, HAN J K, HOPKINS C, et al. Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial. Br J Clin Pharmacol 2024; 90:1952-63.
CANONICA G W, HARRISON T W, CHANEZ P, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy 2022; 77:150-61.
TAKABAYASHI T, ASAKA D, OKAMOTO Y, et al. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis. Am J Rhinol Allergy 2021; 35:861-70.
TVERSKY J, LANE A P, AZAR A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial. Clin Exp Allergy 2021; 51: 836-44.
BACHERT C, HAN J K, DESROSIERS M Y, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol 2022; 149: 1309-17.e12.
HART T K, COOK R M, ZIA-AMIRHOSSEINI P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001; 108:250-7.
BüTTNER C, LUN A, SPLETTSTOESSER T, et al. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003; 21:799-803.
FLOOD-PAGE P T, MENZIES-GOW A N, KAY A B, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199-204.
MENZIES-GOW A, FLOOD-PAGE P, SEHMI R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111:714-9.
FLOOD-PAGE P, SWENSON C, FAIFERMAN I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-71.
ANTONIU S A. Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia. Expert Opin Investig Drugs 2009; 18:869-71.
HALDAR P, BRIGHTLING C E, HARGADON B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-84.
NAIR P, PIZZICHINI M M, KJARSGAARD M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-93.
PAVORD I D, KORN S, HOWARTH P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651-9.
ORTEGA H G, LIU M C, PAVORD I D, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198-207.
CHUPP G L, BRADFORD E S, ALBERS F C, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; 5:390-400.
BEL E H, WENZEL S E, THOMPSON P J, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189-97.
LUGOGO N, DOMINGO C, CHANEZ P, et al. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clin Ther 2016; 38:2058-70.e1.
KHATRI S, MOORE W, GIBSON P G, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2019; 143:1742-51.e7.
KHURANA S, BRUSSELLE G G, BEL E H, et al. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clin Ther 2019; 41:2041-56.e5.
PELAIA C, CRIMI C, PELAIA G, et al. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy 2020; 50:780-8.
KALLIERI M, ZERVAS E, KATSOULIS K, et al. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis. Int Arch Allergy Immunol 2020; 181:613-7.
SCHLEICH F, GRAFF S, NEKOEE H, et al. Real-word experience with mepolizumab: Does it deliver what it has promised? Clin Exp Allergy 2020; 50:687-95.
DOMINGO RIBAS C, CARRILLO DíAZ T, BLANCO APARICIO M, et al. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study. Drugs 2021; 81:1763-74.
ORTEGA H G, YANCEY S W, MAYER B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4:549-56.
ORTEGA H, MENZIES-GOW A, LLANOS J P, et al. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab. Adv Ther 2018; 35:1059-68.
SHRIMANKER R, KEENE O, HYNES G, et al. Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis. Am J Respir Crit Care Med 2019; 200:1308-12.
GUPTA A, IKEDA M, GENG B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol 2019; 144:1336-42.e7.
JACKSON D J, BACHARIER L B, GERGEN P J, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet 2022; 400: 502-11.
GUPTA A, POULIQUEN I, AUSTIN D, et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol 2019; 54:1957-67.
PAVORD I D, CHANEZ P, CRINER G J, et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med 2017; 377:1613-29.
FOKKENS W J, LUND V J, HOPKINS C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58:1-464.
HOX V, LOURIJSEN E, JORDENS A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy 2020; 10:1.
HOPKINS C, BROWNE J P, SLACK R, et al. Complications of surgery for nasal polyposis and chronic rhinosinusitis: the results of a national audit in England and Wales. Laryngoscope 2006; 116:1494-9.
BACHERT C, SOUSA A R, HAN J K, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol 2022; 149: 1711-21.e6.
HAN J K, BACHERT C, FOKKENS W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021; 9:1141-53.
FOKKENS W, TRIGG A, LEE S E, et al. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study. J Patient Rep Outcomes 2023; 7:4.
MULLOL J, LUND V J, WAGENMANN M, et al. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE. Rhinology 2024; 62:320-9.
CHUPP G, ALOBID I, LUGOGO N L, et al. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. J Allergy Clin Immunol Pract 2023; 11:3504-12.e2.
FOKKENS W J, MULLOL J, KENNEDY D, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis. Allergy 2023; 78:812-21.
DESROSIERS M, DIAMANT Z, CASTELNUOVO P, et al. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up. Int Forum Allergy Rhinol 2024; 14:18-31.
LE FLOC'H A, ALLINNE J, NAGASHIMA K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy 2020; 75:1188-204.
WENZEL S, FORD L, PEARLMAN D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455-66.
CORREN J, CASTRO M, CHANEZ P, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol 2019; 122:41-9.e2.
BACHARIER L B, MASPERO J F, KATELARIS C H, et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med 2021; 385:2230-40.
FIOCCHI A G, PHIPATANAKUL W, ZEIGER R S, et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J 2023;62.
WECHSLER M E, FORD L B, MASPERO J F, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med 2022; 10:11-25.
WENZEL S, CASTRO M, CORREN J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388:31-44.
BUSSE W W, MASPERO J F, RABE K F, et al. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther 2018; 35:737-48.
CASTRO M, CORREN J, PAVORD I D, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 2018; 378:2486-96.
CORREN J, CASTRO M, O'RIORDAN T, et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract 2020; 8:516-26.
CORREN J, KATELARIS C H, CASTRO M, et al. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. Eur Respir J 2021;58.
RABE K F, NAIR P, BRUSSELLE G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med 2018; 378:2475-85.
DOMINGO C, MASPERO J F, CASTRO M, et al. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. J Allergy Clin Immunol Pract 2022; 10:1835-43.
SHER L D, WECHSLER M E, RABE K F, et al. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial. Chest 2022; 162:46-55.
DUPIN C, BELHADI D, GUILLEMINAULT L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy 2020; 50:789-98.
BHATT S P, RABE K F, HANANIA N A, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med 2023; 389:205-14.
JAROENPUNTARUK V, PONGDEE T. A Phase 3 Trial of Dupilumab for People With Chronic Obstructive Pulmonary Disease and Elevated Peripheral Blood Eosinophil Counts. J Allergy Clin Immunol Pract 2024; 12:1394-6.
BHATT S P, RABE K F, HANANIA N A, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med 2024; 390: 2274-83.
BACHERT C, MANNENT L, NACLERIO R M, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. Jama 2016; 315:469-79.
BACHERT C, HAN J K, DESROSIERS M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394:1638-50.
BACHERT C, ZINREICH S J, HELLINGS P W, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology 2020; 58:10-7.
MULLOL J, BACHERT C, AMIN N, et al. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps. J Allergy Clin Immunol Pract 2022; 10:1086-95.e5.
HOPKINS C, MULLOL J, KHAN A H, et al. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps. Otolaryngol Head Neck Surg 2024; 170:1173-82.
BACHERT C, HELLINGS P W, MULLOL J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 2020; 75:148-57.
LEE S E, HOPKINS C, MULLOL J, et al. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies. Allergy 2022; 77:2211-21.
DESROSIERS M, MANNENT L P, AMIN N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology 2021; 59:301-11.
HOPKINS C, WAGENMANN M, BACHERT C, et al. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2021; 11:1087-101.
FUJIEDA S, MATSUNE S, TAKENO S, et al. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. Allergy 2022; 77:186-96.
MOUSSION C, ORTEGA N, GIRARD J P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 2008;3:e3331.
SCOTT I C, MAJITHIYA J B, SANDEN C, et al. Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage. Sci Rep 2018; 8:3363.
ALLINNE J, SCOTT G, LIM W K, et al. IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation. J Allergy Clin Immunol 2019; 144:1624-37.e10.
JOHNSTON L K, HSU C L, KRIER-BURRIS R A, et al. IL-33 Precedes IL-5 in Regulating Eosinophil Commitment and Is Required for Eosinophil Homeostasis. J Immunol 2016; 197:3445-53.
WECHSLER M E, RUDDY M K, PAVORD I D, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med 2021; 385:1656-68.
RABE K F, CELLI B R, WECHSLER M E, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med 2021; 9:1288-98.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Huizi Wu, Lan Huang, Yan Liu
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
